Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer

Overview of attention for article published in New England Journal of Medicine, July 2026

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

news: 20 news outlets
blogs: 3 blogs
twitter: 97 X users

reddit: 1 Redditor
bluesky: 15 Bluesky users

Readers on

mendeley: 58 Mendeley

So far, Altmetric has seen 106 X posts from 97 X users, with an upper bound of 1,431,284 followers.

RT @SeeFisch: Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer | New England Journal of Medicine https://t.co/h9Zh…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 102 additional X posts.